BioCentury | Dec 1, 2020
Deals

Viracta to start pivotal trial as public company following Sunesis merger, private placement

...“insufficient evidence of activity in BTK-inhibitor resistant B-cell malignancies.”Its next most advanced program is preclinical PDK1...
...up $0.36 (24%) to $1.86 on Monday.TARGETSBtk – Bruton’s tyrosine kinaseEBV - Epstein-Barr virusPDK1 - Pyruvate dehydrogenase kinase 1 Paul...
BioCentury | May 28, 2020
Distillery Therapeutics

Reducing kidney damage in lupus by targeting HIF1A

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Inhibiting HIF1A could treat lupus by reducing hypoxia-mediated kidney damage by T cells. In renal biopsies from systemic lupus erythematosus patients, tissue with high T cell infiltration had higher...
BioCentury | Feb 8, 2019
Product R&D

Reducing R(i)SK in TNBC

...cells to undergo apoptosis,” Dunn said. “When we did our screens, if you individually inhibited PDK1...
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...PKD and are required for the cystic kidney disease to develop in mice. In homozygous PDK1-knockout...
BioCentury | Aug 18, 2016
Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase α (PI3Kα); pyruvate dehydrogenase kinase 1 (PDK1); serum/glucocorticoid regulated kinase 1 (SGK1)

...Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting PDK1 or SGK1...
...correlated with resistance to chemotherapy. In human PI3Kα inhibitor-resistant breast cancer cell lines, shRNA targeting PDK1...
...of PI3Kα inhibitor-resistant breast cancer, alpelisib plus shRNA targeting PDK1 or SGK1, alpelisib plus a PDK1...
BioCentury | Feb 11, 2016
Translation in Brief

Sugar rush

Partikula LLC is developing a series of compounds that elevate glucose and deplete lactate in the tumor microenvironment by modulating metabolism in tumors. Preclinical data for the lead compound - the tumor-targeted pyruvate dehydrogenase kinase (PDK)...
BioCentury | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Pyruvate dehydrogenase kinase 2 (PDK2); PDK4

Neurology INDICATION: Pain Mouse studies suggest dual PDK2 / PDK4 inhibitors could help treat inflammatory pain. In mice, intraplantar administration of an inflammatory adjuvant increased hindpaw expression of PDK2 and PDK4 compared with vehicle. In...
BioCentury | May 22, 2014
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Restenosis Pyruvate dehydrogenase kinase 2 (PDK2) Rodent, rabbit and porcine studies suggest inhibiting PDK2 in coronary artery transplants could prevent restenosis. In rodent and...
Items per page:
1 - 10 of 24